Search results for " Antineoplastic [Medical Subject Headings]"

showing 10 items of 136 documents

Synthesis of Triazenoazaindoles: a New Class of Triazenes with Antitumor Activity

2011

Despite improvements in the treatment and prevention of cancer, the number of new diagnoses continues to rise; this has fuelled substantial interest in the development of new and effective chemotherapeutic agents. Compounds of the triazene class, such as dacarbazine, have been used in the clinical management of many cancer types including brain, leukemia, and melanoma. A new compound class bearing a triazenoazaindole scaffold was synthesized with the aim of identifying new antiproliferative agents. Compounds 5 a-g and 6 a-c were screened against a panel of human tumor cell lines, and two of them, 5 e and 5 f, showed cytotoxicity (GI(50) range: 2.2-8.2 μM) in all cell lines. These two compou…

Programmed cell deathIndolesToxicology and Pharmaceutics (all)DacarbazineAntineoplastic AgentsAntiproliferative activityPharmacologyEGF receptorsDrug Screening AssaysBiochemistryCell LineFlow cytometryCell Line TumorNeoplasmsDrug DiscoveryTriazenoazaindolemedicineHumansTriazeno derivativesGeneral Pharmacology Toxicology and PharmaceuticsCytotoxicityPharmacologyAntitumor agentsTumorEpidermal Growth Factormedicine.diagnostic_testChemistryMelanomaOrganic ChemistryCancerAntitumorTriazenoazaindoles; Dacarbazine; Antitumor Activitymedicine.diseaseErbB ReceptorsDacarbazineApoptosisCell cultureMolecular MedicineDrug Screening Assays AntitumorAntitumor ActivityTriazenesTriazenoazaindolesAntiproliferative activity; Antitumor agents; EGF receptors; Triazeno derivatives; Antineoplastic Agents; Cell Line Tumor; Dacarbazine; Drug Screening Assays Antitumor; Humans; Indoles; Neoplasms; Receptor Epidermal Growth Factor; Triazenes; Pharmacology Toxicology and Pharmaceutics (all); Organic Chemistry; Molecular MedicineReceptormedicine.drugChemMedChem
researchProduct

Peroxisomal and mitochondrial status of two murine oligodendrocytic cell lines (158N, 158JP): potential models for the study of peroxisomal disorders…

2009

International audience; In some neurodegenerative disorders (leukodystrophies) characterized by myelin alterations, the defect of peroxisomal functions on myelin-producing cells (oligodendrocytes) are poorly understood. The development of in vitro models is fundamental to understanding the physiopathogenesis of these diseases. We characterized two immortalized murine oligodendrocyte cell lines: a normal (158N) and a jimpy (158JP) cell line mutated for the proteolipid protein PLP/DM20. Fluorescence microscopy, flow cytometry, and western blotting analysis allow to identify major myelin proteins (PLP colocalizing with mitochondria; myelin basic protein), oligodendrocyte (CNPase and myelin oli…

Proteolipid protein 1BiochemistryMiceMyelinMESH : PhenylbutyratesperoxisomeIsomerasesMESH : Myelin Basic ProteinsEnoyl-CoA HydrataseCell Line TransformedUltrasonographybiologyMESH : Gene Expression RegulationMESH : Myelin Proteolipid Protein3-Hydroxyacyl CoA DehydrogenasesMESH : Myelin-Associated GlycoproteinMESH : Cell Line TransformedPeroxisomeMESH : Multienzyme ComplexesMESH : OligodendrogliaMESH : Enoyl-CoA HydrataseCatalaseFlow CytometryMESH : 3-Hydroxyacyl CoA DehydrogenasesPhenylbutyratesmitochondriaMyelin-Associated GlycoproteinOligodendrogliamyelinMESH : Antineoplastic Agentsmedicine.anatomical_structureMESH : Microscopy Electron TransmissionBiochemistryACOX1MESH : MitochondriaMESH : Acyl-CoA Oxidase2'3'-Cyclic-Nucleotide PhosphodiesterasesMESH : IsomerasesOxidation-ReductionMyelin ProteinsMESH : Flow CytometryAntineoplastic AgentsPeroxisomal Bifunctional EnzymeStatistics NonparametricMyelin oligodendrocyte glycoproteinCellular and Molecular NeuroscienceMicroscopy Electron TransmissionMultienzyme ComplexesMESH : CatalaseMESH : MicePeroxisomesmedicineAnimalsMESH : ATP-Binding Cassette TransportersMyelin Proteolipid ProteinMESH : Statistics Nonparametric[ SDV.BBM ] Life Sciences [q-bio]/Biochemistry Molecular BiologyMESH : Oxidation-ReductionMyelin Basic Proteinmurine oligodendrocytesMESH : 2'3'-Cyclic-Nucleotide PhosphodiesterasesPeroxisomal transportOligodendrocyteMyelin basic proteinGene Expression Regulationbiology.proteinATP-Binding Cassette TransportersMyelin-Oligodendrocyte GlycoproteinAcyl-CoA OxidaseMESH : AnimalsMESH : Peroxisomes
researchProduct

The Long and Winding Road to Useful Predictive Factors for Anti-EGFR Therapy in Metastatic Colorectal Carcinoma: The KRAS/BRAF Pathway

2010

Monoclonal antibodies targeting the epidermal growth factor receptor (EGFR) have improved outcomes for patients with metastatic colorectal carcinoma. Among patients not carrying activating mutations in the KRAS gene, only a limited number will experience tumor response to these therapeutic agents. The role of BRAF mutations in determining resistance to this treatment is emerging through preclinical and clinical studies. Standardization and validation of laboratory mutation analysis is needed to allow an optimal use of anti-EGFR therapies in the management of colorectal carcinoma. Clinical single-arm and randomized studies were conducted both in first-line and refractory settings to evaluate…

Proto-Oncogene Proteins B-rafCancer ResearchPrognosiColorectal cancerCetuximabColorectal Neoplasmmedicine.disease_causeBRAFProto-Oncogene Proteins p21(ras)FOLFOXProto-Oncogene ProteinsAntineoplastic Combined Chemotherapy ProtocolsKRASmedicineHumansPanitumumabEpidermal growth factor receptorBRAF; Cetuximab; Colorectal carcinoma; KRAS; Panitumumab; Predictive factors; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Humans; Mutation; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Receptor Epidermal Growth Factor; Signal Transduction; ras Proteins; Cancer Research; OncologyneoplasmsProto-Oncogene ProteinClinical Trials as TopicAntineoplastic Combined Chemotherapy ProtocolCetuximabbiologybusiness.industryPanitumumabGeneral Medicineras ProteinPrognosismedicine.diseasedigestive system diseasesOxaliplatinErbB ReceptorsColorectal carcinomaOncologyMutationras ProteinsCancer researchFOLFIRIbiology.proteinReceptor Epidermal Growth FactorKRASPredictive factorColorectal NeoplasmsbusinessHumanSignal Transductionmedicine.drugOncology
researchProduct

Aza-isoindolo and isoindolo-azaquinoxaline derivatives with antiproliferative activity

2015

Abstract Three new ring systems, pyrido[2′,3′:3,4]pyrrolo[1,2- a ]quinoxalines, pyrido[3′,2′:3,4]pyrrolo[1,2- a ]quinoxalines and pyrido[2′,3′:5,6]pyrazino[2,1- a ]isoindoles, were synthesized through an aza-substitution on the already active isoindolo-quinoxaline system and in particular in the position 7 or 4 of the isoindole moiety and in position 5 of the quinoxaline portion. All new compounds were screened by the National Cancer Institute (Bethesda, MD) against a panel of 60 human tumor cell lines. Biological results of the most active derivatives, with pGI 50 values between 7.09 and 7.27, confirmed the importance of the presence of methoxy substituents for biological activity. The ant…

QuinoxalineIsoindolesAzaisoindolo-quinoxalinesStereochemistryAntiproliferative activity; Apoptosis; Azaisoindolo-quinoxalines; DNA interaction; Isoindolo-azaquinoxalines; Quinoxalines; Antineoplastic Agents; Apoptosis; Aza Compounds; Cell Line Tumor; Cell Proliferation; Dose-Response Relationship Drug; Drug Screening Assays Antitumor; Humans; Isoindoles; Molecular Structure; Quinoxalines; Structure-Activity Relationship; Drug Discovery3003 Pharmaceutical Science; Organic Chemistry; Pharmacology; Medicine (all)ApoptosisAntineoplastic AgentsAntiproliferative activityIsoindolesRing (chemistry)Drug Screening AssaysCell LineDose-Response Relationshipchemistry.chemical_compoundStructure-Activity RelationshipQuinoxalineCell Line TumorQuinoxalinesDrug DiscoverymedicineMoietyHumansAntiproliferative activity; Apoptosis; Azaisoindolo-quinoxalines; DNA interaction; Isoindolo-azaquinoxalines; Quinoxalines; Drug Discovery3003 Pharmaceutical Science; Organic Chemistry; PharmacologyCell ProliferationPharmacologyAza CompoundsAzaisoindolo-quinoxalineTumorDose-Response Relationship DrugMolecular StructureDrug Discovery3003 Pharmaceutical ScienceMedicine (all)Organic ChemistryApoptosiBiological activityGeneral MedicineAntitumorCell cycleSettore CHIM/08 - Chimica FarmaceuticaDNA interactionSettore ING-IND/22 - Scienza E Tecnologia Dei MaterialiMechanism of actionchemistryIsoindolo-azaquinoxalineDrug Screening Assays Antitumormedicine.symptomDrugIsoindoleIsoindolo-azaquinoxalines
researchProduct

The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib

2020

Background and aims The present study aims to investigate the role of the prognostic nutritional index (PNI) on survival in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. Methods This multicentric study included a training cohort of 194 HCC patients and three external validation cohorts of 129, 76 and 265 HCC patients treated with Sorafenib, respectively. The PNI was calculated as follows: 10 × serum albumin (g/dL) + 0.005 × total lymphocyte count (per mm3). Univariate and multivariate analyses were performed to investigate the association between the covariates and the overall survival (OS). Results A PNI cut-off value of 31.3 was established using the ROC an…

RNA virusesMaleEtiologyCancer TreatmentHepacivirusKaplan-Meier EstimateBiochemistryCohort StudiesWhite Blood CellsMathematical and Statistical TechniquesRetrospective StudieAnimal CellsAdult; Aged; Aged 80 and over; Antineoplastic Agents; Carcinoma Hepatocellular; Cohort Studies; Female; Humans; Italy; Kaplan-Meier Estimate; Liver Neoplasms; Lymphocyte Count; Male; Middle Aged; Prognosis; Retrospective Studies; Serum Albumin; Sorafenib; Nutrition AssessmentMedicine and Health Sciences80 and overLymphocytesPathology and laboratory medicineAged 80 and overHepatitis C virusLiver DiseasesStatisticsQLiver NeoplasmsRMedical microbiologyMiddle AgedSorafenibPrognosisOncologyItalyLiver NeoplasmPhysical SciencesVirusesMedicineFemalePathogensCellular TypesHumanResearch ArticleAdultHepatitis B virusCarcinoma HepatocellularImmune CellsScienceImmunologyAntineoplastic AgentsGastroenterology and HepatologySerum Albumin ...Research and Analysis MethodsCarcinomasMicrobiologyAlbuminsGastrointestinal TumorsHumansLymphocyte CountStatistical MethodsSerum AlbuminAgedRetrospective StudiesBlood CellsAdult Aged 80 and over Antineoplastic Agents Carcinoma Hepatocellular Cohort Studies Female Humans Italy Kaplan-Meier Estimate Liver Neoplasms Lymphocyte Count Male Middle Aged Prognosis Retrospective Studies Serum Albumin Sorafenib Nutrition AssessmentBiology and life sciencesFlavivirusesCarcinomaViral pathogensOrganismsCancers and NeoplasmsProteinsHepatocellularHepatocellular CarcinomaCell Biologyprognostic nutritional index (PNI) hepatocellular carcinoma (HCC) sorafenib. survival mRECISTHepatitis virusesMicrobial pathogensNutrition AssessmentMultivariate AnalysisCohort StudieMathematics
researchProduct

Resveratrol as a Chemopreventive Agent: A Promising Molecule for Fighting Cancer

2006

International audience; Resveratrol (3,4',5 tri-hydroxystilbene) is a phytoalexin produced in hudge amount in grapevine skin in response to infection by Bothrytis cinerea. This production of resveratrol blocks the proliferation of the pathogen, thereby acting as a natural antibiotic. Numerous studies have reported interesting properties of trans-resveratrol as a preventive agent against important pathologies i.e. vascular diseases, cancers, viral infection or neurodegenerative processes. Moreover, several epidemiological studies have revealed that resveratrol is probably one of the main microcomponents of wine responsible for its health benefits such as prevention of vaso-coronary diseases …

Radiation-Sensitizing AgentsMESH : Radiation-Sensitizing AgentsAngiogenesisClinical BiochemistryTumor initiationPharmacologyResveratrolBiologyMESH : Antineoplastic Agents Phytogenicmedicine.disease_causeMESH : Anticarcinogenic AgentsMESH : Stilbeneschemistry.chemical_compoundNeoplasmsMESH : Cell CycleStilbenesDrug DiscoverymedicineAnimalsAnticarcinogenic AgentsHumansCytotoxicity[ SDV.BBM ] Life Sciences [q-bio]/Biochemistry Molecular BiologyPharmacologychemistry.chemical_classificationPhytoalexinMESH : HumansCell Cyclefood and beveragesCancerCell cyclemedicine.diseaseMESH : NeoplasmsAntineoplastic Agents PhytogenicchemistryResveratrolMolecular MedicineMESH : AnimalsCarcinogenesisCurrent Drug Targets
researchProduct

Entrectinib: a potent new TRK, ROS1, and ALK inhibitor

2015

Abstract: Introduction: Receptor tyrosine kinases (RTKs) and their signaling pathways, control normal cellular processes; however, their deregulation play important roles in malignant transformation. In advanced non-small cell lung cancer (NSCLC), the recognition of oncogenic activation of specific RTKs, has led to the development of molecularly targeted agents that only benefit roughly 20% of patients. Entrectinib is a pan-TRK, ROS1 and ALK inhibitor that has shown potent anti-neoplastic activity and tolerability in various neoplastic conditions, particularly NSCLC. Areas covered: This review outlines the pharmacokinetics, pharmacodynamics, mechanism of action, safety, tolerability, pre-cl…

Receptor Protein-Tyrosine KinasesEntrectinibNTRK1NTRK2NTRK3Receptor tyrosine kinaseEntrectinibMalignant transformationAntineoplastic AgentNeoplasmsProtein-Tyrosine KinaseALK; colorectal cancer; Entrectinib; non-small cell lung cancer; NTRK1; NTRK2; NTRK3; precision medicine; ROS1; salivary gland cancer; TrkA; TrkB; TrkC; Animals; Antineoplastic Agents; Benzamides; Humans; Indazoles; Neoplasms; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Receptor; trkA; Receptor; trkB; Receptor; trkC; Pharmacology; Pharmacology (medical)Anaplastic Lymphoma KinasePharmacology (medical)salivary gland cancerProto-Oncogene ProteinbiologyTrkAPharmacology. TherapyTrkCTrkBGeneral MedicineProtein-Tyrosine KinasesReceptor Protein-Tyrosine KinaseBenzamidesmedicine.symptomROS1ReceptorHumanIndazolesmedicine.drug_classprecision medicineAntineoplastic Agentscolorectal cancerBenzamideProto-Oncogene ProteinsmedicineROS1AnimalsHumansReceptor trkBReceptor trkCReceptor trkAnon-small cell lung cancerPharmacologyAnimalReceptor Protein-Tyrosine KinasesALK inhibitorIndazoleMechanism of actionALKTrk receptorbiology.proteinCancer researchNeoplasmALK; colorectal cancer; Entrectinib; non-small cell lung cancer; NTRK1; NTRK2; NTRK3; precision medicine; ROS1; salivary gland cancer; TrkA; TrkB; TrkC; Animals; Antineoplastic Agents; Benzamides; Humans; Indazoles; Neoplasms; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Receptor trkA; Receptor trkB; Receptor trkC; Pharmacology; Pharmacology (medical)Expert Opinion on Investigational Drugs
researchProduct

Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations

2016

Invasive fungal infections (IFIs) are an important cause of morbidity and mortality in immunocompromised patients. Patients with hematological malignancies undergoing conventional chemotherapy, autologous or allogeneic hematopoietic stem cell transplantation are considered at high risk, and Aspergillus spp. represents the most frequently isolated micro-organisms. In the last years, attention has also been focused on other rare molds (e.g., Zygomycetes, Fusarium spp.) responsible for devastating clinical manifestations. The extensive use of antifungal prophylaxis has reduced the infections from yeasts (e.g., candidemia) even though they are still associated with high mortality rates. This pa…

Riskmedicine.medical_specialtySettore MED/06 - Oncologia Medicamedicine.medical_treatmentHematopoietic stem cell transplantationNeutropeniaSettore MED/17 - MALATTIE INFETTIVEHematopoietic stem cell transplantation; Leukemia; Molds; Risk factors; Yeast; Antineoplastic Combined Chemotherapy Protocols; Disease Susceptibility; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Invasive Fungal Infections; Risk; Hematology; OncologyHematopoietic stem cell transplantation; Leukemia; Molds; Risk factors; Yeast; Hematology; OncologyMolds03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansIn patientAspergillusHematologyLeukemiabiologyIncidence (epidemiology)IncidenceHematopoietic Stem Cell TransplantationHematologyhematopoietic stem cell transplantation; Leukemia; Molds; Risk factors; Yeastmedicine.diseasebiology.organism_classificationYeastSettore MED/15 - MALATTIE DEL SANGUELeukemiaOncologyRisk factorsMold030220 oncology & carcinogenesisHematologic NeoplasmsRisk stratificationImmunologyhematopoietic stem cell transplantationRisk factorDisease SusceptibilityInvasive Fungal Infections030215 immunology
researchProduct

Laparoscopic surgical management of localized recurrent ovarian cancer: a single-institution experience

2014

Background: Optimally, secondary cytoreduction is acknowledged as a valid option in terms of oncologic outcome for patients with platinum-sensitive recurrent ovarian cancer. In cases of localized relapse, a laparoscopic approach has been attempted at various institutions, but studies on its role for this subset of patients still are limited. This report describes the authors' experience using laparoscopic secondary cytoreduction for patients with localized recurrent ovarian cancer. The results from a retrospective analysis of a prospective case series are reported. Methods: Between October 2011 and May 2013, 29 patients with localized recurrent ovarian cancer were selected for a laparoscopi…

Secondary cytoreductionmedicine.medical_treatmentTissue AdhesionsPostoperative ComplicationsLaparotomyLaparoscopyOvarian Neoplasmsmedicine.diagnostic_testMedicine (all)Middle Agedovarian cancerChemotherapy AdjuvantLymphatic MetastasisFemaleAdult; Aged; Antineoplastic Agents; Carcinoma; Chemotherapy; Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Humans; Laparoscopy; Laparotomy; Length of Stay; Lymph Node Excision; Lymphatic Metastasis; Middle Aged; Monitoring; Intraoperative; Neoplasm Recurrence; Local; Neoplasm Staging; Operative Time; Ovarian Neoplasms; Postoperative Complications; Retrospective Studies; Tissue AdhesionsAdultmedicine.medical_specialtyRecurrent ovarian cancer; Laparoscopy; Secondary cytoreductionOperative TimeAntineoplastic AgentsDisease-Free SurvivalLaparoscopicMonitoring IntraoperativeInternal medicineCarcinomamedicineHumansAgedNeoplasm StagingRetrospective StudiesLaparotomybusiness.industryGeneral surgeryCarcinomaRetrospective cohort studyLength of StayHepatologymedicine.diseaseSurgerySettore MED/40 - GINECOLOGIA E OSTETRICIARecurrent Ovarian CancerLymph Node ExcisionSurgeryLaparoscopyNeoplasm Recurrence LocalRecurrent ovarian cancerOvarian cancerbusinessFollow-Up StudiesAbdominal surgery
researchProduct

The Chaperone System in Salivary Glands: Hsp90 Prospects for Differential Diagnosis and Treatment of Malignant Tumors

2022

Salivary gland tumors represent a serious medical problem and new tools for differential diagnosis and patient monitoring are needed. Here, we present data and discuss the potential of molecular chaperones as biomarkers and therapeutic targets, focusing on Hsp10 and Hsp90. The salivary glands are key physiological elements but, unfortunately, the information and the means available for the management of their pathologies, including cancer, are scarce. Progress in the study of carcinogenesis has occurred on various fronts lately, one of which has been the identification of the chaperone system (CS) as a physiological system with presence in all cells and tissues (including the salivary gland…

Settore BIO/16 - Anatomia UmanaOrganic ChemistryAntineoplastic AgentsGeneral MedicineSettore MED/08 - Anatomia PatologicaSalivary Gland NeoplasmsSalivary GlandsCatalysisComputer Science ApplicationsDiagnosis DifferentialInorganic ChemistryHumanschaperone system differential diagnosis Ganetespib Hsp90 Hsp90 biomarker Hsp90 pathogenic negative chaperonotherapysalivary gland tumors Diagnosis Differential Humans Molecular Chaperones Salivary Glands Antineoplastic Agents Salivary Gland NeoplasmsHSP90 Heat-Shock ProteinsPhysical and Theoretical Chemistrysalivary gland tumors; chaperone system; Hsp90; Hsp90 pathogenic; negative chaperonotherapy; Ganetespib; Hsp90 biomarker; differential diagnosisMolecular BiologySpectroscopyMolecular Chaperones
researchProduct